Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Covaxin is not approved in the USA for any age group
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
12-week certificate course commences on March 10th 2022
Company expects strong organic growth in sales, EBITDA in 2022
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
Subscribe To Our Newsletter & Stay Updated
